Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to misleading statements regarding the safety of its clinical trial for RP-A501, which led to significant investor losses following a serious adverse event [2][4][5]. Group 1: Company Overview - Rocket Pharmaceuticals, Inc. is a publicly traded company on NASDAQ under the ticker RCKT [2]. - The company has faced scrutiny for its handling of clinical trial protocols and communication with investors [4][5]. Group 2: Legal Proceedings - A federal securities class action has been filed against Rocket Pharmaceuticals, with a deadline of August 11, 2025, for investors to seek the role of lead plaintiff [2][7]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [7]. Group 3: Financial Impact - Following the announcement of a clinical hold by the FDA due to a serious adverse event, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [6]. Group 4: Investor Communication - Faruqi & Faruqi encourages investors who suffered losses to contact them directly to discuss their legal options [1][8]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3].

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly misleading investors regarding the viability and efficacy of its RP-A501 drug, particularly in relation to its Phase 2 clinical trial for Danon disease [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Rocket Pharmaceuticals misrepresented the reliability of information regarding the projected timeline and safety of the RP-A501 trial, leading to a false sense of security among investors [2]. - Following the announcement of a Serious Adverse Event (SAE) involving a patient in the trial, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, reflecting a significant loss in market value [3]. Group 2: Company Background - Rocket Pharmaceuticals is described as a fully integrated, late-stage biotechnology company focused on developing gene therapies for rare and severe diseases, with a direct on-target mechanism of action and clear clinical endpoints [1].

NEW YORK, June 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/rocket-pharmaceuticals-i ...

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly providing misleading information regarding the safety and clinical trial protocol of its product RP-A501, leading to inflated stock prices and subsequent investor losses [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025 [1]. - The lawsuit claims that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about the safety of RP-A501, including the risk of Serious Adverse Events (SAEs) [5]. - The company allegedly amended the trial protocol without informing shareholders, which contributed to artificially inflated stock prices [5]. Group 2: Investor Actions - Investors who purchased securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by August 11, 2025, to represent the class in the lawsuit [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

DISCLAIMER Various statements in this presentation concerning Rocket's future expectations, plans and prospects that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward- looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Al ...

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the trial following a Serious Adverse Event [2][3]. Group 1: Allegations and Events - The class period for the lawsuit is from February 27, 2025, to May 26, 2025 [2]. - Allegations include that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) [2]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [2]. - On May 27, 2025, Rocket announced a clinical hold on the RP-A501 Phase 2 pivotal study after a patient suffered a SAE, which ultimately resulted in death [2]. - Following this announcement, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action lawsuit by August 11, 2025, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [4].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Rocket Pharmaceuticals, Inc. for alleged misrepresentations regarding the safety and clinical trial protocol of its drug RP-A501, which is intended for treating Danon disease [1][3]. Group 1: Lawsuit Details - The lawsuit covers investors who purchased Rocket's securities between February 27, 2025, and May 26, 2025 [1]. - Defendants are accused of failing to disclose serious risks associated with the clinical trial, including Serious Adverse Events (SAEs) and participant deaths [3]. - The company allegedly modified the trial protocol to include a new immunomodulatory agent without informing shareholders [3]. Group 2: Legal Process - Interested parties wishing to serve as lead plaintiff must file by August 11, 2025 [4]. - Serving as lead plaintiff is not a requirement for sharing in any potential recovery from the lawsuit [4]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [5]. - The firm has been recognized multiple times for its success in litigating class actions [5].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements about its clinical trials and the safety of its gene therapy product RP-A501 [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Ho v. Rocket Pharmaceuticals, Inc. and covers purchasers of Rocket Pharmaceuticals securities from February 27, 2025, to May 26, 2025 [1]. - The lawsuit alleges that Rocket Pharmaceuticals provided misleading information regarding the Phase 2 trial of RP-A501 for Danon disease, particularly concerning the safety and clinical trial protocol [3]. - It is claimed that the company failed to disclose serious adverse events, including participant deaths, and made significant protocol amendments without informing investors [3][4]. Group 2: Impact on Stock - Following the announcement of a clinical hold by the U.S. Food and Drug Administration on May 27, 2025, due to serious adverse events, Rocket Pharmaceuticals' stock price experienced a decline [4]. Group 3: Legal Process - Investors who purchased Rocket Pharmaceuticals securities during the class period can seek appointment as lead plaintiff in the lawsuit, with the lead plaintiff representing the interests of all class members [5]. - The lead plaintiff has the authority to select a law firm for the litigation, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [5]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been recognized for its significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [6].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Rocket Pharmaceuticals and its officers or directors [1] Group 1: Company Developments - On May 27, 2025, Rocket Pharmaceuticals announced an update regarding its investigational gene therapy RP-A501 for Danon disease, revealing that a patient in the Phase 2 trial experienced a Serious Adverse Event (SAE) related to capillary leak syndrome [3] - Following the SAE, Rocket paused further dosing in the study, and the FDA placed a clinical hold on the trial for further evaluation [3] - The patient involved in the SAE subsequently passed away due to an acute systemic infection [3] - As a result of this news, Rocket's stock price dropped by $3.94 per share, or 62.84%, closing at $2.33 per share on May 27, 2025 [3] Group 2: Legal and Investigative Actions - Pomerantz LLP is reaching out to investors of Rocket Pharmaceuticals to investigate claims of potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/rocket-pharmaceuticals-inc-loss-submission-form/?id=153455&from=3 CLA ...